Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
Placebo
Linagliptin
Placebo
Placebo
Placebo
Glimepiride
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion criteria:
Type 2 diabetic male and female patients according to the following criteria:
Based upon a complete medical history and clinical laboratory tests
- Age >= 18 and Age <= 65 years
- Body mass index >= 25 <= 35 kg/m2
- HbA1c <= 7.5%
- Treatment with metformin (=1500 mg daily) for <= 3 months
Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation.
For female patients of childbearing potential:
- Use of acceptable method of contraception (Pearl-Index <1).
Exclusion criteria:
- Treatment with any glucose-lowering drug except for metformin within prior 3 months.
- Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance.
- Any evidence of a clinically relevant acute concomitant disease
- History of cardiovascular disease (e.g. coronary artery disease history of acute myocard infarction or stroke, peripheral vascular disease).
- History of major diabetic complications (e.g. nephropathy, retinopathy)
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, immunological or hormonal disorders (except: hypertension treated with angiotensin receptor blocker or angiotensin-converting-enzyme inhibitors, hyperlipidemia with statin therapy, thyroid hormone replacement therapy, all stable for at least three months prior to screening).
- Surgery of the gastrointestinal tract (except appendectomy).
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.
- History of relevant orthostatic hypotension, fainting spells or blackouts.
- Chronic or relevant acute infections.
- History of relevant allergy/hypersensitivity (including allergy to drug or its excipients).
- Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial.
- Participation in another trial with an investigational drug within one month prior to administration or during the trial.
- Smoker (>= 1 cigarettes or >= 1 cigars or >= 1 pipes/day).
- Alcohol abuse (more than 60 g/day).
- Drug abuse.
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial).
- Excessive physical activities (within one week prior to administration or during the trial).
- Any laboratory value outside the reference range that is of clinical relevance.
Sites / Locations
- 1218.105.001 Boehringer Ingelheim Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Placebo Comparator
Arm Label
Linagliptin 5mg
Glimepiride
Placebo
Arm Description
given once daily over 28 days
given once daily in 1mg dosis over 7 days, following a titration step to 2mg and application for 21 days
given once daily over 28 days
Outcomes
Primary Outcome Measures
Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28
Endothelial function under fasted condition was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
Secondary Outcome Measures
Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28
Endothelial function 2 hours post meal was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28
Endothelial function 2h post-meal was measured by endothelial independent vasodilation (EIDV). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
Number of Patients With Adverse Events
Number of patients with any adverse events
Full Information
NCT ID
NCT01703286
First Posted
October 1, 2012
Last Updated
January 12, 2015
Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
1. Study Identification
Unique Protocol Identification Number
NCT01703286
Brief Title
Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
Official Title
Randomized, Three Period Cross Over, Double Blind, Double Dummy Study in Type 2 Diabetic Patients to Assess the Endothelial Effects of Linagliptin, Glimepiride and Placebo Therapy for 28 Days ('ENDOTHELINA')
Study Type
Interventional
2. Study Status
Record Verification Date
January 2015
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
January 2014 (Actual)
Study Completion Date
January 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
4. Oversight
5. Study Description
Brief Summary
The general aim of the present study is to investigate the impact of 4 weeks treatment with linagliptin (5 mg) on endothelial function in patients with type 2 diabetes mellitus. In the current trial this effect of linagliptin treatment on endothelial function will be compared against both the sulfonylurea glimepiride and against placebo, which has not been tested in a trial before; as also is the case for other DPP-4 inhibitors.
Besides placebo, glimepiride was chosen as a comparator, as it is one compound of the second most used oral antidiabetic drug class.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
42 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Linagliptin 5mg
Arm Type
Experimental
Arm Description
given once daily over 28 days
Arm Title
Glimepiride
Arm Type
Active Comparator
Arm Description
given once daily in 1mg dosis over 7 days, following a titration step to 2mg and application for 21 days
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
given once daily over 28 days
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo matching Glimepiride
Intervention Type
Drug
Intervention Name(s)
Linagliptin
Intervention Description
given once daily for 28 days
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo matching Linagliptin
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo matching Linagliptin
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo matching Glimepiride
Intervention Type
Drug
Intervention Name(s)
Glimepiride
Intervention Description
1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
Primary Outcome Measure Information:
Title
Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28
Description
Endothelial function under fasted condition was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
Time Frame
baseline and day 28 for each treatment arm
Secondary Outcome Measure Information:
Title
Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28
Description
Endothelial function 2 hours post meal was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
Time Frame
baseline and day 28 for each treatment arm
Title
Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28
Description
Endothelial function 2h post-meal was measured by endothelial independent vasodilation (EIDV). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
Time Frame
baseline and day 28 for each treatment arm
Title
Number of Patients With Adverse Events
Description
Number of patients with any adverse events
Time Frame
up to 20 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Type 2 diabetic male and female patients according to the following criteria:
Based upon a complete medical history and clinical laboratory tests
Age >= 18 and Age <= 65 years
Body mass index >= 25 <= 35 kg/m2
HbA1c <= 7.5%
Treatment with metformin (=1500 mg daily) for <= 3 months
Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation.
For female patients of childbearing potential:
Use of acceptable method of contraception (Pearl-Index <1).
Exclusion criteria:
Treatment with any glucose-lowering drug except for metformin within prior 3 months.
Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance.
Any evidence of a clinically relevant acute concomitant disease
History of cardiovascular disease (e.g. coronary artery disease history of acute myocard infarction or stroke, peripheral vascular disease).
History of major diabetic complications (e.g. nephropathy, retinopathy)
Gastrointestinal, hepatic, renal, respiratory, cardiovascular, immunological or hormonal disorders (except: hypertension treated with angiotensin receptor blocker or angiotensin-converting-enzyme inhibitors, hyperlipidemia with statin therapy, thyroid hormone replacement therapy, all stable for at least three months prior to screening).
Surgery of the gastrointestinal tract (except appendectomy).
Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.
History of relevant orthostatic hypotension, fainting spells or blackouts.
Chronic or relevant acute infections.
History of relevant allergy/hypersensitivity (including allergy to drug or its excipients).
Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial.
Participation in another trial with an investigational drug within one month prior to administration or during the trial.
Smoker (>= 1 cigarettes or >= 1 cigars or >= 1 pipes/day).
Alcohol abuse (more than 60 g/day).
Drug abuse.
Blood donation (more than 100 mL within four weeks prior to administration or during the trial).
Excessive physical activities (within one week prior to administration or during the trial).
Any laboratory value outside the reference range that is of clinical relevance.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1218.105.001 Boehringer Ingelheim Investigational Site
City
Neuss
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
28109295
Citation
Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovasc Diabetol. 2017 Jan 21;16(1):13. doi: 10.1186/s12933-016-0493-3.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/
Description
Related Info
Learn more about this trial
Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
We'll reach out to this number within 24 hrs